Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Being told that a scan looks suspicious after stomach cancer treatment can bring back many of the fears you thought you had already dealt with. But a suspicious scan does not always provide the complete answer.
When doctors suspect recurrent gastric cancer, they usually need to answer several questions: Has the cancer definitely returned? Where is it? Has it spread elsewhere? Can tissue be obtained safely? And has the biology of the cancer changed in a way that could affect treatment?
There is therefore rarely one single “recurrence test.” Diagnosis usually combines your symptoms and medical history with imaging, laboratory tests and, when appropriate, endoscopy or biopsy. Current guidelines emphasize CT imaging and endoscopic tissue diagnosis as important parts of gastric-cancer assessment.
Key Takeaways |
|
What Does Recurrent Gastric Cancer Mean?
Recurrent gastric cancer means stomach cancer has returned after previous treatment.
The recurrence can occur in different ways. It may develop around the original stomach or surgical area, in nearby lymph nodes, on the lining of the abdominal cavity—the peritoneum—or in distant organs such as the liver or lungs.
That distinction matters because the location and extent of recurrence can substantially change what doctors recommend next.
Some recurrences are discovered during follow-up imaging before the patient develops major symptoms. Others are investigated because the patient notices something new.
ESMO recommends follow-up after gastric-cancer treatment to investigate symptoms and detect recurrence, with follow-up tailored to the individual patient and original stage of disease.
What Symptoms Can Suggest Stomach Cancer Has Returned?
There is no symptom that proves gastric cancer has returned.
However, certain new or persistent problems can lead your oncology team to investigate further. These can include abdominal discomfort, reduced appetite, feeling full quickly, unexplained weight loss, difficulty swallowing, nausea or vomiting, gastrointestinal bleeding, anemia or increasing weakness and fatigue.
The symptoms depend partly on where the recurrence is located.
For example, recurrence involving the peritoneum can sometimes cause fluid accumulation in the abdomen, while disease involving the liver or distant lymph nodes may produce a different pattern of symptoms.
Importantly, these symptoms can also have non-cancer causes. Previous stomach surgery and cancer treatment can themselves produce long-term digestive and nutritional problems.
That is why symptoms usually trigger investigation, rather than being considered proof of recurrence.
What Scans are Used to Diagnose Recurrent Gastric Cancer?
CT scan
A contrast-enhanced CT scan is one of the most important imaging tests when doctors suspect recurrence.
Doctors can use CT imaging to examine areas such as the abdomen, pelvis and chest for evidence of recurrent or metastatic disease.
A 2026 American College of Radiology review considers contrast-enhanced CT of the abdomen and pelvis an appropriate primary imaging method for surveillance after curative gastric-cancer surgery and for detecting recurrence.
Doctors may look for findings such as new masses, enlarged lymph nodes, liver lesions, peritoneal abnormalities, ascites or changes around the previous surgical area.
However, imaging findings sometimes remain uncertain. An abnormality on a CT scan is not automatically recurrent cancer, which is why comparison with previous scans and additional testing can be important.
PET/CT
A PET/CT scan may sometimes be used when doctors need additional information about possible recurrence or distant disease.
The 2026 ACR criteria consider FDG-PET/CT appropriate in certain post-treatment settings, including assessment for distant recurrence.
However, PET/CT has limitations in gastric cancer. ESMO notes that FDG-PET may be less informative in some diffuse-type or mucinous gastric cancers because these tumors can have lower FDG uptake. It is therefore not routinely required for every patient.
MRI
MRI is not necessarily the first scan used for every recurrence, but it can provide more detailed evaluation of particular abnormalities.
For example, doctors may use MRI to characterize certain liver lesions or when additional anatomical detail is needed. The appropriate imaging approach depends on what earlier scans have shown.
Do I Need Another Endoscopy and Biopsy?
Not every patient with suspected recurrence requires another endoscopy, but it can be important when recurrence is suspected in an area accessible from the upper gastrointestinal tract.
During an upper endoscopy, a flexible camera is passed through the mouth and esophagus to examine the upper digestive tract. Suspicious tissue can then be sampled.
Endoscopy with biopsy remains the gold-standard method for obtaining tissue to diagnose gastric cancer. ESMO recommends multiple biopsy samples when diagnosing gastric tumors so that there is adequate tissue for pathological and molecular assessment.
For recurrent disease, the biopsy location may be different from the original tumor. If the suspicious disease is in the liver, lymph nodes or another distant location, doctors may instead consider an image-guided biopsy.
Whether a repeat biopsy is worthwhile depends on its safety, accessibility and whether the result could change treatment.
Why Might Doctors Test the Tumor Again After Recurrence?
A biopsy can do more than confirm that cancer is present.
It can provide tissue for biomarker testing, which may influence treatment decisions in recurrent or metastatic gastric cancer.
Important biomarkers can include:
HER2
HER2 testing can help determine whether HER2-directed therapy may be appropriate.
PD-L1
PD-L1 expression, usually reported using a combined positive score (CPS), can be relevant when considering certain immunotherapy strategies.
MSI/MMR
Testing for microsatellite instability or mismatch-repair deficiency can identify tumors for which immune-based treatment may be particularly relevant.
CLDN18.2
Claudin 18.2 has become another clinically important biomarker in gastric cancer.
The Pan-Asian adapted ESMO guidelines identify HER2, PD-L1 and MSI-H/dMMR as validated predictive biomarkers and state that CLDN18.2 expression may also be examined when available.
This is particularly relevant for patients exploring newer gastric-cancer treatments and clinical trials.
Can Recurrent Gastric Cancer Be Missed on a CT Scan?
It is possible for some disease to be difficult to see clearly on standard imaging.
One particular challenge is peritoneal disease, where gastric cancer spreads across the lining of the abdominal cavity. Very small deposits may not always be obvious on imaging.
In selected situations, doctors may therefore consider diagnostic laparoscopy. This involves inserting a small camera into the abdomen so that the peritoneal surfaces can be inspected directly. Fluid or washings can also be collected and examined for malignant cells.
Laparoscopy is well established in the staging of potentially resectable gastric cancer because it can identify peritoneal disease that was not apparent on scans.
Whether it is appropriate during a recurrence work-up depends on the individual clinical situation and whether the result would alter treatment.
What Happens After Recurrent Gastric Cancer is Confirmed?
Confirmation of recurrence is not the end of the diagnostic process.
The oncology team then needs to establish how much disease is present and what treatment options remain.
Doctors will review where the recurrence is located, how quickly it appeared after previous treatment, which treatments you have already received, your general health and the molecular characteristics of the tumor.
This information may determine whether doctors discuss systemic chemotherapy, targeted therapy, immunotherapy, selected local treatments or clinical trials.
For patients who have already received several treatment lines, the clinical-trial question can become increasingly important.
China is one country with substantial gastric-cancer research activity, including studies involving CLDN18.2-targeted therapies, immunotherapy and cellular approaches. This does not mean that every patient with recurrent gastric cancer should travel to China. It means that, once the recurrence and tumor characteristics are clearly documented, additional treatment programs can be investigated where appropriate.
Should I Get a Second Opinion After a Recurrent Gastric Cancer Diagnosis?
A second opinion can be particularly useful when the recurrence is unexpected, imaging findings are unclear, the cancer has returned after several treatments or the proposed next step involves a major treatment decision.
The second specialist may review your original pathology, new biopsy, CT or PET/CT images, previous treatments and molecular testing.
Sometimes the second opinion confirms exactly what your existing oncology team has recommended.
That can still be valuable.
In other cases, the review may identify additional testing that should be completed before treatment begins, or it may identify a clinical trial or treatment approach that deserves further discussion.
How ChinaCureLink Can Help Patients With Recurrent Gastric Cancer
For international patients considering treatment options in China, ChinaCureLink can help organize medical records and coordinate case evaluation with appropriate Chinese cancer centers.
Ideally, this happens before international travel.
A case package may include pathology reports, biopsy information, actual imaging files, surgery records, previous chemotherapy or immunotherapy history and molecular testing.
If important biomarkers such as HER2, PD-L1, MSI/MMR or CLDN18.2 have not been evaluated, the reviewing team may determine whether additional testing is relevant.
Where appropriate, ChinaCureLink can also help patients explore Chinese hospital programs and clinical trials involving newer approaches to gastric cancer.
The goal is not to assume that China is appropriate for every recurrence. It is to establish the diagnosis and tumor characteristics first, then determine whether a specific specialist, hospital or research program may have something relevant to offer.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions
What Test Confirms Recurrent Gastric Cancer?
There is no single test used in every patient. Doctors commonly combine imaging—particularly CT—with medical history and examination. When feasible and clinically useful, a biopsy can provide pathological confirmation of recurrent cancer.
Is a CT Scan Enough to Diagnose Recurrent Stomach Cancer?
CT is one of the main tests used to detect recurrence, but additional testing may sometimes be required. Depending on the location and uncertainty of the findings, doctors may recommend endoscopy, biopsy, PET/CT, MRI or other investigations.
Do I Need Another Biopsy If Stomach Cancer Comes Back?
Not always. A repeat biopsy may be recommended when confirmation is needed or when new tissue could provide biomarker information that affects treatment. Doctors must balance the potential benefit against the safety and accessibility of the biopsy.
What Biomarkers are Tested in Recurrent Gastric Cancer?
HER2, PD-L1 and MSI/MMR are important predictive biomarkers in advanced gastric cancer. CLDN18.2 may also be tested where available and clinically relevant.
Can Gastric Cancer Recurrence Occur Without Symptoms?
Yes. Some recurrences are discovered on follow-up imaging before significant symptoms develop. Follow-up after treatment should therefore be individualized according to the original cancer, treatment and patient's clinical situation.
Should I Seek a Second Opinion If My Stomach Cancer Has Returned?
A second opinion can help when the diagnosis is uncertain, important treatment decisions are being made or you want another specialist to review pathology, imaging, biomarkers and possible clinical trials.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
European Society for Medical Oncology (ESMO). Gastric Cancer: Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Annals of Oncology, 2022. ESMO guideline
Shitara K, et al. Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis, Treatment and Follow-up of Patients with Gastric Cancer. ESMO Open, 2024. Pan-Asian ESMO guideline
National Cancer Institute. Stomach Cancer Diagnosis and Tests. NCI stomach cancer diagnosis guide
American College of Radiology. ACR Appropriateness Criteria: Staging and Follow-up of Gastric Cancer. 2026. ACR gastric cancer imaging guidance